Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Core One Labs Inc C.COOL

Alternate Symbol(s):  CLABF

Core One Labs Inc. is a Canada-based life sciences biotechnology research and development company. The Company is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of delivery systems technology. Its subsidiary, Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its subsidiary Akome Biotech Ltd., and three provisional patents under its other subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods. It also holds an interest in four medical clinics, which maintain a combined database of more than 275,000 patients.


CSE:COOL - Post by User

Bullboard Posts
Comment by Leafs4Lifeon Nov 21, 2017 12:03pm
131 Views
Post# 27004093

RE:RE:RE:Clarification on most recent article:

RE:RE:RE:Clarification on most recent article:

sandra2017 wrote: And how have the fundamentals changed in the last two days Leafs??  I'll wait till she settles down into the 40s again.


The CEO of the company made revenue projections of 30 million in 2017 and 64 million in 2018. The company was valued around 40 million last week. If you think it deserves to trade at 1.25X 2017 sales, then you don't understand fundamental analysis or technical analysis. 

There has also been promotional work bringing this story to the eyes of a lot of investors who didn't know the story. 

And we will be able to verify the CEO's claims in early December when he reports the first month of sales. Oh, yeah, that's another thing that's changed, LDS is finally executing on its business plan instead of building facilities and raising money. The market is in "show me" mode and we will get a chance to see in less than 3 weeks. 

That's what's changed. But welcome to the party.  

Bullboard Posts